Literature DB >> 28226363

Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study.

Amit Tirosh1, Maya Lodish1, Charalampos Lyssikatos1, Elena Belyavskaya1, Richard A Feelders2, Constantine A Stratakis1.   

Abstract

Previous studies reported a higher prevalence of venous-thromboembolic events among patients with Cushing disease (CD) compared to those with ACTH-independent Cushing syndrome (CS) from adrenal sources. The objective of the current study was to evaluate the coagulation profile of patients with CS from different etiologies. A prospective observational study was conducted at a clinical research center. The study included adult patients admitted for evaluation of suspected CS (n=85), that were divided into 3 groups: CD (n=22), ACTH-independent CS from an adrenal tumor/hyperplasia (adrenal CS, n=21), and a control group consisting of subjects with negative screening for CS (rule-out CS, n=42). Coagulation profiles were drawn before and 8.5±4.3 months after surgery (trans-sphenoidal or adrenalectomy, n=18), and included fibrinogen, Factor VIII (FVIII), von Willebrand factor antigen (vWF:Ag), plasminogen activator inhibitor-1 (PAI-1), antithrombin III (ATIII), Protein C (PC), Protein S (PS), α2-antiplasmin (α2AP), and aPTT measurements. Patients with CD had higher baseline mean cortisol levels, ATIII activity and vWF:Ag levels compared with adrenal CS. Differences in ATIII activity and vWF:Ag levels remained even after controlling for BMI, and ATIII after also controlling for 24-h urinary free cortisol collections. Our study showed for the first time the differences in coagulation profiles between various etiologies of CS. We assume that the higher cortisol burden among CD patients may explain the differences found in the coagulation profile as well as the higher risk for VTE compared with primary adrenal CS patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28226363      PMCID: PMC6533628          DOI: 10.1055/s-0043-100113

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  27 in total

1.  Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure.

Authors:  A Colao; R Pivonello; S Spiezia; A Faggiano; D Ferone; M Filippella; P Marzullo; G Cerbone; M Siciliani; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

2.  The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state.

Authors:  G M Patrassi; M T Sartori; M L Viero; L Scarano; M Boscaro; A Girolami
Journal:  Blood Coagul Fibrinolysis       Date:  1992-12       Impact factor: 1.276

3.  Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk.

Authors:  Libuse Tauchmanovà; Riccardo Rossi; Bernadette Biondi; Melania Pulcrano; Vincenzo Nuzzo; Emiliano-Antonio Palmieri; Serafino Fazio; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

4.  Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin?

Authors:  Ilse Mertens; Robert V Considine; Marc Van der Planken; Luc F Van Gaal
Journal:  Eur J Endocrinol       Date:  2006-09       Impact factor: 6.664

5.  Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome.

Authors:  A Casonato; E Pontara; M Boscaro; N Sonino; F Sartorello; S Ferasin; A Girolami
Journal:  Blood Coagul Fibrinolysis       Date:  1999-04       Impact factor: 1.276

6.  Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.

Authors:  Marco Boscaro; Nicoletta Sonino; Alessandro Scarda; Luisa Barzon; Francesco Fallo; Maria T Sartori; Giovanni M Patrassi; Antonio Girolami
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

7.  Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers.

Authors:  Darko Kastelan; Tina Dusek; Ivana Kraljevic; Ozren Polasek; Zlatko Giljevic; Mirsala Solak; Silva Zupancic Salek; Jozo Jelcic; Izet Aganovic; Mirko Korsic
Journal:  Endocrine       Date:  2009-04-21       Impact factor: 3.633

Review 8.  Hypercoagulable state in Cushing's syndrome: a systematic review.

Authors:  Bregje Van Zaane; Erfan Nur; Alessandro Squizzato; Olaf M Dekkers; Marcel Th B Twickler; Eric Fliers; Victor E A Gerdes; Harry R Büller; Dees P M Brandjes
Journal:  J Clin Endocrinol Metab       Date:  2009-05-19       Impact factor: 5.958

9.  Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

Authors:  C Erem; I Nuhoglu; M Yilmaz; M Kocak; A Demirel; O Ucuncu; H Onder Ersoz
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

10.  Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome.

Authors:  L M Fatti; B Bottasso; C Invitti; R Coppola; F Cavagnini; P M Mannucci
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 5.467

View more
  4 in total

Review 1.  Cushing's Syndrome in Pediatrics: An Update.

Authors:  Maya B Lodish; Margaret F Keil; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

2.  Is VTE Prophylaxis Necessary on Discharge for Patients Undergoing Adrenalectomy for Cushing Syndrome?

Authors:  Bruna Babic; Amory De Roulet; Anita Volpe; Naris Nilubol
Journal:  J Endocr Soc       Date:  2018-12-12

3.  High Perceived Stress May Shorten Activated Partial Thromboplastin Time and Lead to Worse Clinical Outcomes in Patients With Coronary Heart Disease.

Authors:  Han Yin; Xingyu Cheng; Yanting Liang; Anbang Liu; Haochen Wang; Fengyao Liu; Lan Guo; Huan Ma; Qingshan Geng
Journal:  Front Cardiovasc Med       Date:  2021-11-29

4.  Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).

Authors:  F M van Haalen; M Kaya; I C M Pelsma; O M Dekkers; N R Biermasz; S C Cannegieter; M V Huisman; B J M van Vlijmen; R A Feelders; F A Klok; A M Pereira
Journal:  Orphanet J Rare Dis       Date:  2022-05-03       Impact factor: 4.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.